In:
Oncology Research and Treatment, S. Karger AG, Vol. 44, No. 9 ( 2021), p. 450-468
Abstract:
〈 b 〉 〈 i 〉 Introduction: 〈 /i 〉 〈 /b 〉 The prognosis of advanced hepatocellular carcinoma (HCC) varies in patients receiving transcatheter arterial chemoembolization (TACE). In this study, we aimed to assess the prognostic value of serum apolipoprotein B (ApoB)/apolipoprotein A-I (ApoA-I) in this group of patients. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 The serum lipid levels of HCC patients undergoing TACE were obtained from routine preoperative blood lipid examination. A propensity score-matched (PSM) analysis was used to eliminate the imbalance of baseline characteristics of the high and low ApoB/ApoA-I groups. Then, univariate and multivariate analysis were conducted to evaluate the prognostic value of ApoB/ApoA-I. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 In 455 HCC patients treated with TACE, ApoB/ApoA-I was positively correlated with AFP, T stage, distant metastasis, and TNM stage ( 〈 i 〉 p 〈 /i 〉 & #x3c; 0.05). Patients with high ApoB/ApoA-I had a significantly shorter overall survival (OS) than those with low ApoB/ApoA-I (median OS, 21.7 vs. 39.6 months, 〈 i 〉 p 〈 /i 〉 & #x3c; 0.001). Multivariate analysis indicated that ApoB/ApoA-I was an independent prognostic index for OS (hazard ratio [HR] = 1.42, 〈 i 〉 p 〈 /i 〉 = 0.008). After baseline characteristics were balanced, 288 patients were included in the PSM cohort. In this cohort, high ApoB/ApoA-I still predicted inferior OS in both univariate analysis (median OS, 27.6 vs. 39.3 months, 〈 i 〉 p 〈 /i 〉 = 0.002) and multivariate analysis (HR = 1.58, 〈 i 〉 p 〈 /i 〉 = 0.006). 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 Serum ApoB/ApoA-I is a useful biomarker in predicting aggressive clinicopathological characteristics and poor prognosis in HCC patients treated with TACE.
Type of Medium:
Online Resource
ISSN:
2296-5270
,
2296-5262
Language:
English
Publisher:
S. Karger AG
Publication Date:
2021
detail.hit.zdb_id:
2749752-5
Permalink